Biogen’s pivotal moment: Will the FDA approve the experimental — and controversial — Alzheimer’s-disease drug aducanumab?
June 02, 2021 at 13:24 PM EDT
U.S. regulators are expected to decide whether to approve Biogen’s experimental Alzheimer’s disease drug sometime this week, a decision that could send the company’s stock price soaring or tumbling depending on the outcome.